SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Aurobindo Pharma informs about proceedings of AGM

03 Aug 2022 Evaluate

Aurobindo Pharma has informed that in continuation to letter dated July 7, 2022, the 35th Annual General Meeting (AGM) of the Company was held on August 2, 2022 and the business mentioned in the AGM Notice dated June 17, 2022 was transacted. In this regard, it enclosed the following: Summary of proceedings as required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as Annexure-I, Voting Results as required under Regulation 44 of the SESI (Listing Obligations and Disclosure Requirements) Regulations 2015 as Annexure-II and The Report of Scrutinizer on remote e-voting and voting at AGM (by electronic means) as Annexure- III.

The above information is a part of company’s filings submitted to BSE.

Aurobindo Pharma Share Price

1413.80 -22.10 (-1.54%)
24-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1619.95
Dr. Reddys Lab 1315.85
Cipla 1294.75
Zydus Lifesciences 927.15
Lupin 2296.10
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×